Navigation Links
Sequenom Announces Participation at Jefferies 2011 Global Healthcare Conference
Date:5/26/2011

SAN DIEGO, May 26, 2011 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM)), a life sciences company providing innovative genetic analysis solutions, today announced the Company's participation at the Jefferies 2011 Global Healthcare Conference at the Grand Hyatt Hotel in New York City, June 6-9, 2011.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

Harry F. Hixson, Jr., Ph.D., Chairman and CEO will present on Wednesday, June 8, 2011 beginning at 1:30 p.m. EDT, to provide an overview of and update on the Company. The presentation is expected to last approximately 30 minutes and will be web cast live through the "Investors" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation web cast.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a website at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom website to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

SEQUENOM ® is a trademark of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.


'/>"/>
SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study
2. Sequenom Announces Publication Acceptance of Manuscript From Trisomy 21 R&D Verification Study
3. Sequenom Announces Exercise in Full of Underwriters Option to Purchase Additional Shares
4. Sequenom Announces Formation of Ophthalmology Clinical Advisory Board
5. Sequenom to Present at Two Financial Conferences in September
6. Sequenom to Present at Two Financial Conferences in March
7. Sequenom Appoints Two New Board Members
8. SEQUENOM Announces Partnership With GeneWorks for Sales & Marketing of MassARRAY Systems and Applications in Australia
9. SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
10. SEQUENOM Announces Launch of MassARRAY Compact 96 System
11. SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a ... designed, tuned and optimized exclusively for Okuma CNC machining centers at The International ... a collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
Breaking Biology Technology:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
Breaking Biology News(10 mins):